Alvaro Alonso1, Jeffrey R Misialek2, Erin D Michos3, John Eckfeldt4, Elizabeth Selvin5, Elsayed Z Soliman6, Lin Y Chen7, Myron D Gross4, Pamela L Lutsey2. 1. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, 1200 S 2nd St., Suite 300, Minneapolis, MN 55454, USA alonso@umn.edu. 2. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, 1200 S 2nd St., Suite 300, Minneapolis, MN 55454, USA. 3. Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 4. Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN, USA. 5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 6. Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, USA. 7. Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA.
Abstract
AIMS: To assess the prospective association between circulating 25-hydroxyvitamin D [25(OH)D] and atrial fibrillation (AF) risk. METHODS AND RESULTS: We studied 12 303 participants from the Atherosclerosis Risk in Communities study without baseline AF (1990-92). Baseline serum total 25(OH)D was measured using mass spectrometry. Incident AF cases were identified from electrocardiograms, hospital discharge codes, and death certificates through 2012. We estimated hazard ratios (HRs) and 95% confidence intervals (95% CIs) of AF across clinical categories of serum 25(OH)D concentrations with multivariable Cox models, and tested interactions by age, race, and sex. We meta-analysed our results with those from published prospective studies that reported associations between 25(OH)D and AF risk. During a median follow-up of 21 years, we identified 1866 AF events. In multivariable models, deficient 25(OH)D status (<20 ng/mL), compared with optimal levels (≥30 ng/mL), was not associated with AF risk (HR, 95% CI: 1.10, 0.96-1.26). A significant interaction of 25(OH)D concentrations with age (P = 0.01), but not with race or sex (P > 0.40), was identified, with higher risk of AF among those with deficient 25(OH)D status in younger (HR, 95% CI: 1.35, 1.05-1.73) but not older individuals (HR, 95% CI: 1.02, 0.86-1.21). A meta-analysis of these results and four prospective studies did not support a clinically relevant association of circulating 25(OH)D with AF risk [pooled HR, 95%CI: 1.04, 1.00-1.08, per 1 SD lower 25(OH)D]. CONCLUSION: Low serum 25(OH)D was not associated with incident AF in a community-based cohort and in a meta-analysis of prospective studies. A possible association in younger individuals warrants further investigation. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: To assess the prospective association between circulating 25-hydroxyvitamin D [25(OH)D] and atrial fibrillation (AF) risk. METHODS AND RESULTS: We studied 12 303 participants from the Atherosclerosis Risk in Communities study without baseline AF (1990-92). Baseline serum total 25(OH)D was measured using mass spectrometry. Incident AF cases were identified from electrocardiograms, hospital discharge codes, and death certificates through 2012. We estimated hazard ratios (HRs) and 95% confidence intervals (95% CIs) of AF across clinical categories of serum 25(OH)D concentrations with multivariable Cox models, and tested interactions by age, race, and sex. We meta-analysed our results with those from published prospective studies that reported associations between 25(OH)D and AF risk. During a median follow-up of 21 years, we identified 1866 AF events. In multivariable models, deficient 25(OH)D status (<20 ng/mL), compared with optimal levels (≥30 ng/mL), was not associated with AF risk (HR, 95% CI: 1.10, 0.96-1.26). A significant interaction of 25(OH)D concentrations with age (P = 0.01), but not with race or sex (P > 0.40), was identified, with higher risk of AF among those with deficient 25(OH)D status in younger (HR, 95% CI: 1.35, 1.05-1.73) but not older individuals (HR, 95% CI: 1.02, 0.86-1.21). A meta-analysis of these results and four prospective studies did not support a clinically relevant association of circulating 25(OH)D with AF risk [pooled HR, 95%CI: 1.04, 1.00-1.08, per 1 SD lower 25(OH)D]. CONCLUSION: Low serum 25(OH)D was not associated with incident AF in a community-based cohort and in a meta-analysis of prospective studies. A possible association in younger individuals warrants further investigation. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Paul N Jensen; Karin Johnson; James Floyd; Susan R Heckbert; Ryan Carnahan; Sascha Dublin Journal: Pharmacoepidemiol Drug Saf Date: 2012-01 Impact factor: 2.890
Authors: Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver Journal: J Clin Endocrinol Metab Date: 2011-06-06 Impact factor: 5.958
Authors: Lu Wang; Yiqing Song; Joann E Manson; Stefan Pilz; Winfried März; Karl Michaëlsson; Annamari Lundqvist; Simerjot K Jassal; Elizabeth Barrett-Connor; Cuilin Zhang; Charles B Eaton; Heidi T May; Jeffrey L Anderson; Howard D Sesso Journal: Circ Cardiovasc Qual Outcomes Date: 2012-11-13
Authors: Pamela L Lutsey; Erin D Michos; Jeffrey R Misialek; James S Pankow; Laura Loehr; Elizabeth Selvin; Jared P Reis; Myron Gross; John H Eckfeldt; Aaron R Folsom Journal: JACC Heart Fail Date: 2015-04-08 Impact factor: 12.035
Authors: Alvaro Alonso; Sunil K Agarwal; Elsayed Z Soliman; Marietta Ambrose; Alanna M Chamberlain; Ronald J Prineas; Aaron R Folsom Journal: Am Heart J Date: 2009-07 Impact factor: 4.749
Authors: Anna Vitezova; Natasha S Cartolano; Jan Heeringa; M Carola Zillikens; Albert Hofman; Oscar H Franco; Jessica C Kiefte-de Jong Journal: PLoS One Date: 2015-05-01 Impact factor: 3.240
Authors: Alvaro Alonso; Bouwe P Krijthe; Thor Aspelund; Katherine A Stepas; Michael J Pencina; Carlee B Moser; Moritz F Sinner; Nona Sotoodehnia; João D Fontes; A Cecile J W Janssens; Richard A Kronmal; Jared W Magnani; Jacqueline C Witteman; Alanna M Chamberlain; Steven A Lubitz; Renate B Schnabel; Sunil K Agarwal; David D McManus; Patrick T Ellinor; Martin G Larson; Gregory L Burke; Lenore J Launer; Albert Hofman; Daniel Levy; John S Gottdiener; Stefan Kääb; David Couper; Tamara B Harris; Elsayed Z Soliman; Bruno H C Stricker; Vilmundur Gudnason; Susan R Heckbert; Emelia J Benjamin Journal: J Am Heart Assoc Date: 2013-03-18 Impact factor: 5.501
Authors: Muhammad Ali Anees; Muhammad Imtiaz Ahmad; Parag A Chevli; Yabing Li; Elsayed Z Soliman Journal: Ann Noninvasive Electrocardiol Date: 2019-01-19 Impact factor: 1.468
Authors: Amelie H Ohlrogge; Jan Brederecke; Francisco M Ojeda; Simon Pecha; Christin S Börschel; Lenard Conradi; Vanessa Rimkus; Stefan Blankenberg; Tanja Zeller; Renate B Schnabel Journal: Front Nutr Date: 2022-05-10